Future Science Group
Browse
Supplementary Figure 2.docx (70.29 kB)

Supplementary Figure 2: Resource title* Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points..docx

Download (70.29 kB)
figure
posted on 2021-11-09, 15:15 authored by Ernest Law, Roya Gavanji, Sarah WalshSarah Walsh, Anja Haltner, Rebecca McTavish, Chris Cameron
Supplementary Figure 2

Funding

Pfizer, Inc.

History